This “Immune Thrombocytopenic Purpura - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Immune Thrombocytopenic Purpura pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Immune Thrombocytopenic Purpura - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Immune Thrombocytopenic Purpura Understanding
Immune Thrombocytopenic Purpura: Overview
Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets. The most common symptoms associated with ITP are low platelet count, easy or excessive bruising, superficial bleeding into the skin, mucosal bleeding, blood in urine or stools, and unusual heavy menstrual flow. The risk of developing ITP is more common among young women than men. The diagnosis of ITP is made by physical examination, medical history, and blood test to count the platelets. The tests are done to exclude other causes of thrombocytopenia, including certain medications or disorders that affect the bone marrow and reduce platelet production, such as acute leukemia and aplastic anemia. Treatment for ITP is based on the degree of bleeding occur and the platelet count. First-line treatments for ITP are corticosteroids and intravenous immunoglobulin (IVIG). Second-line treatments include splenectomy, thrombopoietin analogues, and monoclonal antibodies."Immune Thrombocytopenic Purpura - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Immune Thrombocytopenic Purpura R&D. The therapies under development are focused on novel approaches to treat/improve Immune Thrombocytopenic Purpura.Immune Thrombocytopenic Purpura Emerging Drugs Chapters
This segment of the Immune Thrombocytopenic Purpura report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Immune Thrombocytopenic Purpura Emerging Drugs
Rozanolixizumab: UCB
Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. The drug is in Phase III clinical studies for the treatment of immune thrombocytopenia.Mezagitamab: Takeda
Mezagitamab (also known as TAK-079) is a fully human, IgG1 monoclonal antibody targeting CD38. CD38 is a cell surface molecule that is highly expressed on myeloma cells, plasma cells, plasmablasts, and natural killer (NK) cells, and is induced on activated T cells and other suppressor cells including regulatory T (Tregs) and B (Bregs) cells. The drug is in Phase II clinical studies for the treatment of immune thrombocytopenic purpura.Immune Thrombocytopenic Purpura: Therapeutic Assessment
This segment of the report provides insights about the different Immune Thrombocytopenic Purpura drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Immune Thrombocytopenic Purpura
There are approx. 20+ key companies which are developing the therapies for Immune Thrombocytopenic Purpura. The companies which have their Immune Thrombocytopenic Purpura drug candidates in the most advanced stage, i.e. Phase III include, UCB.Phases
The report covers around 20+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Immune Thrombocytopenic Purpura pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Immune Thrombocytopenic Purpura: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpura therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpura drugs.Immune Thrombocytopenic Purpura Report Insights
- Immune Thrombocytopenic Purpura Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Immune Thrombocytopenic Purpura Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Immune Thrombocytopenic Purpura drugs?
- How many Immune Thrombocytopenic Purpura drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenic Purpura?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenic Purpura therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Immune Thrombocytopenic Purpura and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- CThe Pharmaceutical
- Hutchison MediPharma
- UCB Biopharma
- Takeda
- Genosco
- Principia Biopharma (Sanofi)
- argenx
Key Products
- CNP-ITP
- HMPL 523
- Rozanolixizumab
- Mezagitamab
- Cevidoplenib
- Rilzabrutinib
- Efgartigimod
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
Immune Thrombocytopenic Purpura: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Immune Thrombocytopenic Purpura Key Products
Immune Thrombocytopenic Purpura- Unmet Needs
Immune Thrombocytopenic Purpura- Market Drivers and Barriers
Immune Thrombocytopenic Purpura- Future Perspectives and Conclusion
Immune Thrombocytopenic Purpura Analyst Views
Appendix
List of Tables
Table 1 Total Products for Immune Thrombocytopenic Purpura
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Immune Thrombocytopenic Purpura
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Cour Pharmaceutical
- Hutchison MediPharma
- UCB Biopharma
- Takeda
- Genosco
- Principia Biopharma (Sanofi)
- argenx
